Literature DB >> 30847693

Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus?

Reenam S Khan1,2,3,4, Philip N Newsome5,6,7,8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 30847693     DOI: 10.1007/s10620-019-05573-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  11 in total

1.  Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.

Authors:  Yuya Seko; Yoshio Sumida; Kazuyo Sasaki; Yoshito Itoh; Hiroaki Iijima; Toshio Hashimoto; Shinichi Ishii; Nobuya Inagaki
Journal:  J Gastroenterol       Date:  2017-07-01       Impact factor: 7.527

2.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

Authors:  Kenneth Cusi; Beverly Orsak; Fernando Bril; Romina Lomonaco; Joan Hecht; Carolina Ortiz-Lopez; Fermin Tio; Jean Hardies; Celia Darland; Nicolas Musi; Amy Webb; Paola Portillo-Sanchez
Journal:  Ann Intern Med       Date:  2016-06-21       Impact factor: 25.391

3.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 5.  A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.

Authors:  Giovanni Targher; Christopher D Byrne
Journal:  Metab Syndr Relat Disord       Date:  2015-02-25       Impact factor: 1.894

6.  Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.

Authors:  Lee-Lee Lai; Shireene Ratna Vethakkan; Nik Raihan Nik Mustapha; Sanjiv Mahadeva; Wah-Kheong Chan
Journal:  Dig Dis Sci       Date:  2019-01-25       Impact factor: 3.199

Review 7.  Non-alcoholic fatty liver disease and diabetes.

Authors:  Jonathan M Hazlehurst; Conor Woods; Thomas Marjot; Jeremy F Cobbold; Jeremy W Tomlinson
Journal:  Metabolism       Date:  2016-01-11       Impact factor: 8.694

8.  Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.

Authors:  Norio Akuta; Chizuru Watanabe; Yusuke Kawamura; Yasuji Arase; Satoshi Saitoh; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yoshiyuki Suzuki; Fumitaka Suzuki; Kenji Ikeda; Hiromitsu Kumada
Journal:  Hepatol Commun       Date:  2017-02-27

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321

View more
  3 in total

1.  Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Haleh Chehrehgosha; Masoud Reza Sohrabi; Faramarz Ismail-Beigi; Mojtaba Malek; Mohammad Reza Babaei; Farhad Zamani; Hossein Ajdarkosh; Mahmood Khoonsari; Afshin Eshghi Fallah; Mohammad E Khamseh
Journal:  Diabetes Ther       Date:  2021-02-14       Impact factor: 2.945

2.  Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Hoda Taheri; Mojtaba Malek; Faramarz Ismail-Beigi; Farhad Zamani; Masoudreza Sohrabi; Mohammad Reza Babaei; Mohammad E Khamseh
Journal:  Adv Ther       Date:  2020-09-25       Impact factor: 3.845

Review 3.  Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Authors:  Kalliopi Pafili; Michael Roden
Journal:  Mol Metab       Date:  2020-11-19       Impact factor: 7.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.